MILAN, ITALY — The premier global pharmaceutical exhibition, CPHI Milan 2026, took place from October 6 to 8 in Milan, Italy. To actively capture international business opportunities, the Medical and Pharmaceutical Industry Technology and Development Center (PITDC) led the Taiwan Pharmaceutical Alliance (TPA) and a robust delegation of 19 Taiwanese pharmaceutical companies to the event. Showcasing Taiwan's comprehensive expertise across Active Pharmaceutical Ingredients (APIs), generic drugs, and biologics, the delegation successfully demonstrated the nation's industry strengths. Highlighting the tangible success of Taiwan's overseas expansion efforts, TPA member Orient EuroPharma (OEP) Group announced a new partnership agreement with a Middle Eastern pharmaceutical company, closely following a recent contract signed with a Colombian pharmaceutical firm.

The impressive Taiwanese delegation featured prominent industry players, including Chung Mei Pharmaceutical, China Chemical & Pharmaceutical (CCPC), Swiss Pharmaceutical, Peili Pharmaceutical, Standard Chem. & Pharm., Syngen Biotech, Savior Lifetec, Sunny Pharmtech, Yung Zip Chemical, YungShin Pharm, OEP Group, UBI Pharma, Yuan Chou Chemical, Synmosa, Ta Shieh, Sinphar Pharmaceutical, Ming Sheng Biotechnology, PBF, and Center Biotechnology. Through proactive international networking, tailored business matchmaking, and partnership negotiations, these enterprises actively sought global opportunities in R&D, manufacturing, and technology collaboration to accelerate their global market penetration.

PITDC emphasized that participating in major international exhibitions not only helps establish vital overseas business networks but also unlocks diverse avenues for cross-border collaboration. Moving forward, PITDC will continue to support Taiwanese companies in exploring strategic opportunities in new drug R&D, technology licensing, process transfer, Contract Development and Manufacturing (CDMO), and startup innovations. By bridging Taiwan's robust R&D capabilities with global market demands, PITDC aims to deepen bilateral industry collaborations and continuously elevate the global visibility and competitiveness of Taiwan's pharmaceutical sector.

CPHI Milan 2026 is recognized as one of the world's largest and most comprehensive professional exhibitions for pharmaceutical ingredients and technologies. The event integrates the entire pharmaceutical supply chain, spanning APIs, finished formulations, biologics, CDMO services, pharmaceutical equipment, and related solutions. According to the organizers, this year's event was expected to attract over 62,000 pharmaceutical professionals and more than 2,900 exhibiting companies from around the globe, serving as an essential platform for international drug manufacturers and suppliers to exchange technologies, forge business partnerships, and capture the latest global market trends.